Active Ingredient
(in each tablet)
Levocetirizine dihydrochloride 5 mg
The following Structured Product Label (SPL) was submitted to the FDA by Chattem, Inc. for the product Xyzal Allergy 24hr (NDC 41167-3513). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, purpose, uses, do not use, ask a doctor before use if you have, when using this product, stop use and ask a doctor if, if pregnant or breast-feeding:, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
(in each tablet)
Levocetirizine dihydrochloride 5 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other respiratory allergies:
In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
| adults 65 years of age and older | ■ ask a doctor |
| adults and children 12-64 years of age | ■ take 1 tablet (5 mg) once daily in the evening ■ do not take more than 1 tablet (5 mg) in 24 hours ■ ½ tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms |
| children 6-11 years of age | ■ take ½ tablet (2.5 mg) once daily in the evening ■ do not take more than ½ tablet (2.5 mg) in 24 hours |
| children under 6 years of age | ■ do not use |
| consumers with kidney disease | ■ do not use |
(Note: Age ranges are bolded in the draft container labeling for tablet bottle)
(if bottled) safety sealed: do not use if carton was opened or if printed foil inner seal on bottle is torn or missing
(if stretch card) safety sealed: do not use if sealed package was torn or opened, or if printed foil inner seal on bottle is torn or missing
Colloidal anhydrous silica, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, titanium dioxide
call 1-800-633-1610
* Please review the disclaimer below.